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Abstract
Introduction
Bisphenol A (BPA) is an ubiquitous environmental toxin that is also found in dialyzers.
Online hemodiafiltration (OL-HDF) more efficiently clears high molecular weight molecules,
and this may improve BPA clearance. However, the BPA contents of dialysis membranes
may be a source of BPA loading during OL-HDF.
Methods
A prospective study assessed plasma BPA levels in OL-HDF patients using BPA-free (poly-
nephron) or BPA-containing (polysulfone) dialyzers in a crossover design with two arms,
after a run-in OL-HDF period of at least 6 months with the same membrane: 31 patients on
polynephron at baseline were switched to polysulfone membranes for 3 months (polyne-
phron-to-polysulfone) and 29 patients on polysulfone were switched to polynephron for 3
months (polysulfone-to-polynephron).
Results
After a run-in OL-HDF period of at least 6 months with the same membrane, baseline pre-
dialysis BPA was lower in patients on polynephron (8.79±7.97 ng/ml) than in those on poly-
sulfone (23.42±20.38 ng/mL, p<0.01), but still higher than in healthy controls (<2 ng/mL).
After 3 months of polynephron-to-polysulfone switch, BPA was unchanged (8.98±7.88 to
11.14±15.98 ng/mL, ns) while it decreased on the polysulfone-to-polynephron group
(23.42±20.38 to 11.41±12.38 ng/mL, p<0.01).
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Conclusion
OL-HDF for 3 months with BPA-free dialyzer membranes was associated to a significant
decrease in predialysis BPA levels when compared to baseline BPA levels while on a BPA-
containing membrane.
Introduction
Bisphenol A (BPA, 2,2-bis-(4-hydroxyphenyl) propane) is an environmental toxin containing
aromatic rings with structural similarity with phenols, which is present in polycarbonate plas-
tics, epoxy resins and some dialyzer membranes. BPA has biological activity as a chemical
switch in endocrine processes, and may negatively impact reproduction, weight and develop-
ment. The maximum safe oral intake is 4 μg/kg/day [1]
Several studies have linked BPA exposure to the development of obesity, insulin resistance,
metabolic syndrome, diabetes, atherosclerosis, hypertension and pathological albuminuria [2,
3], [4], [5]. One of the arguments used by regulatory agencies for considering BPA safe in the
general population is the almost complete urinary clearance. However, serum BPA levels
increase with decreasing renal function and are highest in individuals on hemodialysis [6].
Therefore, the general safety of BPA in the general population cannot be extrapolated to the
dialysis population, since BPA accumulates in chronic kidney disease (CKD) patients.
Our group recently found lower plasma BPA levels in patients on conventional hemodialy-
sis on BPA-free dialyzers than in those on BPA-containing dialyzers [7]. Thus, dialyzer BPA
content may contribute to BPA burden in conventional hemodialysis patients and these
patients are more sensitive to BPA accumulation and potential toxicity due to the loss of the
physiological BPA excretion mechanisms in urine [7]. These findings differed from the con-
clusion of a prior, short term study, probably due to the slow build-up of BPA accumulation
[8].
Hemodialysis is based on the ability of molecules to diffuse across a semipermeable mem-
brane. Online hemodiafiltration (OL-HDF) improves mid-to-large molecule clearance by
combining diffusive and convective transport [9]. However, high flux dialyzers used in
OL-HDF may contain BPA, thus potentially contributing to the BPA burden. Therefore, the
relative contributions of the OL-HDF technique, the dialyzer composition or the follow-up
time to changes in BPA levels remains to be characterized. Our objective was to prospectively
assess the impact of the BPA contents of dialyzers on plasma BPA levels in OL-HDF patients.
Materials and methods
Clinical design and patient recruitment
The study was approved by the IIS-Fundacio´n Jime´nez Dı´az Ethics Committee and the study
was performed in accordance with the Declaration of Helsinki and the European Union Clini-
cal Trial Directive (2001/20/EC). Patients were enrolled after providing written informed
consent.
In a prospective 9-month, crossover study we compared BPA-free and BPA-containing dia-
lyzers in 72 patients on OL-HDF. Dialyzers only differed in the BPA content in the membrane.
Specifically, BPA-free high-flux polynephron (polynephron) membranes (Elisio, NiproCorp,
Osaka, Japan) were compared with high-flux polysulfone (Helixone1) dialyzers that contain
BPA (Fx80; Fresenius, Bad Homburg, Germany).
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At time zero (initiation of OL-HDF), patients were randomized into polynephron (n = 36)
or.polysulfone (N = 36) dialysis membranes (Figs 1 and 2). No blood sampling was performed
at this time point. This was followed by a run-in period of at least 6 months (Fig 1). Baseline
blood sampling was performed 6 months after the last patient had been enrolled. At baseline,
blood samples for BPA assessment were collected before (Pre-) the first OL-HDF session with
the switch membrane and after (Post-) this first session with the switch membrane. Since this
was a crossover study, we use the term switch membrane to denote the new membrane to
which the patient was switched after baseline predialysis sampling. Thus, the switch membrane
was polysulfone in polynephron-to-polysulfone patients and polynephron in polysulfone-to-
polynephron patients. After three months on the switch membrane, the 3-month blood sample
was obtained, both pre- and post-OL-HDF session with the switch membrane.
The primary end-point was change in pre-dialysis BPA between baseline and three months.
The difference between baseline and three months could only be assessed in the 29 polyne-
phron-to-polysulfone and 31 polysulfone-to-polynephron patients that completed the study
and had a second sample for analysis (Fig 2). In this regard, the analysis should be considered
per protocol and not intention-to-treat.
Blood lines were made of PVC (Fresenius Medical Care) in all cases. OL-HDF was per-
formed with a blood flow >300 ml/min and dialysate flow 500 ml/min, using ultrapure dialysis
fluids, defined as<0.1 CFU/ml and<0.03 EU/ml. The length of dialysis sessions, composition
of dialysate and reinfusate (sodium 138–140 mmol/L, potassium 1.5–2.0 mmol/L, calcium
1.25–1.75 mmol/L, magnesium 0.5 mmol/L, chloride 106–109 mmol/L, bicarbonate 34–37
mmol/L, acetate 3–4 mmol/L, and glucose 1.0 g/L) was not modified during the study. All
patients were on postdilution OL-HDF, with a minimum of 20 L of replacement volume per
session. For on line production of replacement fluid, polysulfone BPA-containing ultrafilters
Fig 1. Study design: Timing of plasma sampling for BPA assessment. Baseline pre-dialysis plasma sampling took place after>6 months
OL-HDF and prior to the first session with the switch dialyzer. Baseline post-dialysis sampling was obtained immediately after the first session
with the switch dialyzer. Sampling was repeated pre- and post-dialysis after 3 months on the switch dialyzer.
https://doi.org/10.1371/journal.pone.0193288.g001
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(DIASAFE1plus; Fresenius, Bad Homburg, Germany) were used to prevent patient contact
with endotoxins and other pyrogenic or bacteria-derived substances. Samples from individuals
with normal renal function used as control samples (n = 10) were obtained from the blood
bank after informed consent. Eighteen patients from the prior conventional hemodialysis
study [7] were also enrolled in the current study.
Clinical and biochemical variables
Fasting blood samples were drawn from the arteriovenous fistula just prior to a midweek dialy-
sis session and plasma was frozen at –80˚C. Blood was sampled before (predialysis) and after
(postdialysis) a single dialysis session to determine BPA changes in one session using polyne-
phron or polysulfone dialyzers. Laboratory parameters were assessed by automated blood ana-
lyzers (Advia 2400 chemistry system and Advia 2120 hematology system, Siemens).
BPA assessment
BPA was measured by a high-sensitivity ELISA (Abnova), following the manufacturer’s
instructions. The intra- and inter-assay coefficients of variation were 6.5% and 10.5%, respec-
tively. This is the same technique used in the prior conventional hemodialysis study.
Statistical analyses
Variables were described at baseline and at 3-month follow-up for each arm of the study, as
mean and standard deviation. Comparisons between values were performed using paired
Fig 2. Patient flow chart.
https://doi.org/10.1371/journal.pone.0193288.g002
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sample t test, Mann-Whitney or Wilcoxon signed-rank test. All comparisons used the bilateral
hypothesis test and a significance level of 0.05. One Way Anova was performed to compare
pre and post-dialysis BPA at baseline and after 3 months. Correlations between BPA values
and clinical variables were assessed using Spearman’s rank correlation coefficient.
Results
Clinical characteristics of patients in hemodiafiltration
Table 1 shows the clinical data of the patients at the initial at the baseline dialysis session and at
3 months after dialyzer switch. No significant differences were observed between baseline and
3 months for the parameters analyzed.
Plasma BPA is lower in OL-HDF than in conventional hemodialysis
patients
We have now analyzed 60 patients that had been on OL-HDF using the same membrane for
more than 6 months. After more than 6 months on OL-HDF with the same membrane, pre-
dialysis BPA concentration was 12.12±15.9 ng/ml (Fig 3). In 18 patients who participated in a
prior study while on hemodialysis [7] before switching to OL-HDF for enrollment in the cur-
rent study, plasma BPA fell from 98.96±120.75 ng/ml while on conventional hemodialysis
to 13.14±13.78 ng/ml (p = 0.017) after more than 6 months on OL-HDF with the same
Table 1. Summary of clinical and biochemical variables.
Polysulfone-to polynephron Polynephron-to-polysulfone
Baseline 3 months Baseline 3 months
Kt/V urea 1.71±0.05 1.78±0.05 1.71±0.03 1.71±0.03
Qb (ml/min) 384.5 ± 49.4 392.9 ± 48.7 377.2 ± 42.4 388.1 ± 47.1
Dialysis time (min) 225.2 ± 12.7 224.4±13.7 219.1 ± 16.5 216.7 ± 16.2
Interdialysis weight gain (kg) 1.9 ± 0.6 1.9±0.6 1.8 ± 0.8 2.0 ± 0.9
Replacement volume (L) 26.4 ± 3.8 26.0±3.8 25.9 ± 4.6 25.7 ± 4.3
Substitution flow (mL/min) 118.74±20.7 117.92±17.6 116.12±10.5 113.95±14.4
Leukocytes (103/μl) 6196±420 6754±514 6500±387 6489±360
Hb (g/dl) 11.48±0.30 11.63±0.27 11.63±0.21 10.91±0.23
25 OH vitamin D (ng/ml) 11.37±1.32 14.39±1.64 12.19±1.36 14.34±1.68
Total protein (g/dl) 6.36±0.11 6.41±0.12 6.64±0.10 6.53±0.11
Albumin (g/dl) 3.56±0.09 3.60±0.10 3.74±0.07 3.76±0.11
Ca (mg/dl) 9.08±0.14 9.20±0.13 9.03±0.10 9.01±0.12
P (mg/dl) 4.16±0.20 4.15±0.24 4.43±0.23 4.65±0.28
Cholesterol (mg/dl) 150±6 147±6 150±5 146±6
Triglycerides (mg/dl) 112±9 106±10 102±11 105±8
CRP (mg/L) 20.77±5.54 16.65±6.11 16.32±4.20 21.36±9.18
PTH (pg/dl) 403±86 421±103 284±37 311±45
Glucose (mg/dl) 136±9 140±12 131±12 125±12
BMI (Kg/m2) 24.76± 0.73 24.82±0.73 25.87±0.89 25.93±0.88
TSH (μUI/mL) 2.72±0.49 2.93±0.59 2.17±0.35 2.36±0.36
T3 (μg/dl) 2.30±0.08 2.54±0.08 2.18±0.07 2.59±0.09
T4 (μg/dl) 1.18±0.04 1.21±0.03 1.11±0.04 1.14±0.04
Cortisol (μg/dl) 11.51± 1.39 10.88±1.17 10.80± 0.87 11.35±0.89
Aldosterone (pg/dl) 296.81±52.03 262.35±57.61 341.25±55.81 238.82±54.08
https://doi.org/10.1371/journal.pone.0193288.t001
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membrane. By membrane, BPA fell from 52.73±60.6 to 6.78±6.48 in patients on polynephron
and from 163.03±155.84 to 19,02±14.46 in patients on polysulfone, although this group of
patients were randomized in switching to HDF.
Healthy individuals have values usually below the limit of quantification of the assay (2 ng/
mL) (Fig 3). In this regard, plasma BPA was 6-fold (p<0.01) and 47-fold (p<0.01) higher in
OL-HDF or conventional hemodialysis patients, respectively, than in the control population,
confirming the accumulation of BPA in patients in end-stage kidney disease (ESRD).
The BPA concentration in replacement fluid was under the limit of detection of assay.
Bisphenol A at baseline and after 3-month cross-over
Predialysis baseline levels (blood sampled before the first dialysis session with the switch dia-
lyzer, Fig 1) vary according to the dialyzer that had been used for >6 months prior to the first
session with the switch dialyzer (Fig 4). In samples obtained just before the first session with
the switch dialyzer, mean BPA levels were 23.42±20.88 ng/mL for patients using polysulfone
dialyzers for>6 months, and 8.98±7.88 ng/mL for patients using polynephron for >6 months
(p<0.01) (Fig 4).
Fig 3. Plasma BPA concentration. Healthy subjects (n = 10); patients on online hemodiafiltration (HDF) (n = 58) and patients
on conventional hemodialysis (HD) who were later enrolled in the present study (n = 18) [7]. Data expressed as mean±SD. For
HD and OL-HDF, values correspond to baseline predialysis values in the switch studies. At this point, patients had been on HD
or OL-HDF for>6 months.  p<0.05;  p = 0.017.
https://doi.org/10.1371/journal.pone.0193288.g003
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Similarly, 3 months after dialyzer cross-over, BPA levels in polynephron-to-polysulfone
patients change from 8.98±7.88 to 11.14±15.98 ng/mL (ns), while in polysulfone-to-polyne-
phron patients, BPA decreased from 23.42±20.88 to 11.42±12.38 ng/mL (p<0.01), a 51%
decrease (Fig 4).
Pre-dialysis and post-dialysis plasma BPA concentration during a single
OL-HDF session
The accumulation or elimination of BPA in a single OL-HDF session depends on the balance
between membrane-leaked BPA and BPA clearance by OL-HDF. In OL-HDF with BPA-free
membranes, only BPA clearance is expected to occur. In the first dialysis session with polyne-
phron membranes following the switch from polysulfone was associated with a decrease in
BPA levels from 23.42±20.88 ng/mL (pre-dialysis) to 6.44±10.77 ng/mL (post-dialysis), a 72%
reduction (p<0.01). By contrast, the first dialysis with polysulfone following the switch from
polynephron did not reduce BPA (pre-dialysis 8.98±7.88 to post-dialysis 8.43±6.99 ng/mL,
ns), suggesting that the BPA load from the polysulfone membrane may have partially offset
BPA clearance by OL-HDF (Fig 4).
After 3 months on polynephron dialyzers, the predialysis serum BPA levels (11.42±12.88
ng/mL) tended to decrease change post-dialysis (7.23±10.98 ng/mL, ns). In patients on
Fig 4. Plasma BPA concentration in patients on OL-HDF with polynephron (PN) or polysulfone (PS) membranes. Pre- and post-dialysis
measurements are shown for the first (baseline) and the last (3-month) session after the switch. Prior to the baseline pre-dialysis sample, patients
had been on OL-HDF with the opposite membrane for>6 months. Thus, baseline pre-dialysis values represent values corresponding to>6
months OL-HDF with the opposite membrane and were used as baseline values for the switch study, while baseline post-dialysis values were
already obtained after the first session with the switch membrane. Data expressed as mean±SD.  p<0.01. Pre- and Post- refers to pre-dialysis
and post-dialysis (OL-HDF) session.
https://doi.org/10.1371/journal.pone.0193288.g004
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polysulfone dialyzers for 3 months, no difference was observed between pre- and post-dialysis
samples (11.14±15.98 to 11.86±10.41 ng/mL) (Fig 4).
BPA levels do not correlate with other laboratory variables
Major laboratory and anthropometric variables associated to hemodialysis, nutritional and
inflammatory status were collected. Correlations between BPA values and these variables were
assessed using Spearman’s rank correlation coefficient. In general, plasma BPA was not associ-
ated to laboratory variables (S1 Table).
Discussion
The main finding of the present study is that in patients on long-term BPA-containing dialyz-
ers, a switch to a BPA-free dialyzer for three months was associated with a decrease in predialy-
sis plasma BPA levels that was not observed in patients switched to BPA-containing dialyzers.
Additionally, long-term (>6 months) use of BPA-free dialyzers was associated with lower pre-
dialysis BPA levels that long-term use of BPA-containing dialyzers.
BPA is a 228 KD protein-bound molecule that accumulates in the circulation and intracel-
lularly in CKD patients and may contribute to CKD manifestations [10]. BPA has been
described to be 95% bound to proteins with an apparent dissociation constant of 2000 nmol/
ml ex vivo [11]. The decrease of 72% in BPA levels during the first OL-HDF session when the
switch membranes were BPA-free membranes is larger than expected for a protein-bound
molecule. However, it is consistent with results from Quiroga et al. who observed an average
reduction of 45% when dialyzers with and without BPA were analyzed as a single group [12].
This is consistent with a 72% reduction with BPA-free membranes and no change with BPA-
containing membranes in our study (the mean of a 72% reduction with BPA free membranes
and a 1% with BPA containing membranes is a 36% reduction, in the range of the 45%
observed by Quiroga et al). This is in contrast to an average reduction ratio during OL-HDF of
5 to 10% for protein-bound uremic toxins [9]. In this regard, the factors modulating the reduc-
tion in BPA levels and BPA protein binding are not well understood. A key difference with
other protein-bound toxins is that BPA can actually be released into the circulation by certain
membranes during dialysis. However, this factor is not active in patients dialyzed with BPA-
free membranes.
OL-HDF has the potential to increase serum BPA due to leaching from BPA-containing
tubing or membranes used in the online production of reinfusion fluids. However, none of
these factors differed between the two arms of the study. Additionally, BPA release from tubing
is considered negligible and BPA was undetectable in the reinfusion fluid. While online pro-
duction of dialysate solutions in the present study was associated to filtering the fluid through
two BPA-containing polysulfone ultrafilters [13], the observation of a BPA-free replacement
fluid is consistent with the observation that BPA leach from dialyzers is higher when blood,
rather than saline, is filtered [14]. This has been ascribed to the presence in blood of hydropho-
bic components such as lipids and lipoproteins. BPA may also leach from BPA-containing dia-
lyzer membranes during OL-HDF [6, 14]. However, no prospective, long-term studies have
assessed the effect of chronic OL-HDF using state-of-the-art dialyzers with different BPA con-
tents. In the present study, BPA levels were much lower in patients on OL-HDF than in
patients that had participated in a conventional hemodialysis study in whom BPA was mea-
sured by the same assay (), independently of the dialysis membrane used. Thus, BPA levels
were higher in the 69 patients in the hemodialysis study (64.55±93.8 ng/ml) [7] and also in
the 18 patients in the hemodialysis study that went on to be enrolled in the present study
(98.96±120.75 ng/ml) than in the patients treated for longer than 6 months with OL-HDF
Bisphenol A in online hemodiafiltration
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(23.42±3.81 ng/mL). The data support the concept advanced by Quiroga et al [12], that he
dialysis technique (OL-FDF vs hemodialysis) indeed results in lower BPA levels. The BPA con-
centration range differed in both studies, probably due to the use of a different BPA assay, to
individual patient or dialysis characteristics, to different duration of the study or to the exis-
tence of limitations to BPA clearance such as continuous leakage from dialyzer membranes
(in the prior studies both BPA-containing and BPA-free membranes were grouped together).
The short-term nature of Quiroga´s study using a heterogeneous group of dialyzers regarding
the BPA contents of the dialyzer membranes did not allow the assessment of the relative con-
tributions of the OL-HDF technique, the dialyzer composition or the follow-up time to the
observed reduction in BPA levels [12]. Our data now point out that dialysis membrane compo-
sition is a key determinant of BPA levels in OL-HDF patients. In this regard, the switch design
allowed an accurate assessment of the impact of dialysis membrane composition on plasma
BPA levels in OL-HDF patients, and results are consistent with the prior hemodialysis study
[7].
Additionally, BPA levels were even lower in OL-HDF patients using BPA-free dialyzer
membranes for >6 months. From the available data, we cannot differentiate between BPA
accumulation during the>6 month run-in with BPA-containing membranes from pre-exis-
tent high BPA values, since no sampling took place at time zero.
We found no relationship between BPA levels and analytical data. This may be related to
the lower levels of BPA in OL-HDF than in conventional hemodialysis or to a low number of
patients, given the complexity and heterogeneity of hemodialysis patients, or to a genuine lack
of a relationship. In this regard, the study was designed to assess BPA levels, not to explore
clinical or biochemical correlates.
This study has some limitations. The number of patients was low and baseline assessment
of BPA concentrations was considered to represent the impact of>6 months of therapy with
each membrane retrospectively. However, no samples were available from time zero (at the
start of the>6 month run-in period).
In conclusion, in OL-HDF patients, BPA-free dialyzers are associated with a long-term
larger decrease in BPA levels than the use of BPA-containing dialyzers, although BPA values at
three months did not differ between the groups. Furthermore, our results support the concept
that OL-HDF is associated with lower BPA levels than conventional high flux hemodialysis,
although in OL-HDF, BPA still remains well above healthy control values. Further studies
should explore the health consequences of BPA accumulation from dialysis membranes in
patients on long-term OL-HDF.
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